Biomarker discovery and beyond for diagnosis of bladder diseases
Molecular biosignatures of altered cellular landscapes and functions have been casually linked with pathological conditions, which imply the promise of biomarkers specific to bladder diseases, such as bladder cancer and other dysfunctions. Urinary biomarkers are particularly attractive due to costs, time, and the minimal and noninvasive efforts acquiring urine. The evolution of omics platforms and bioinformatics for analyzing the genome, epigenome, transcriptome, proteome, lipidome, metabolome, etc., have enabled us to develop more sensitive and disease-specific biomarkers. These discoveries broaden our understanding of the complex biology and pathophysiology of bladder diseases, which can ultimately be translated into the clinical setting. In this short review, we will discuss current efforts on identification of promising urinary biomarkers of bladder diseases and their roles in diagnosis and monitoring. With these considerations, we also aim to provide a prospective view of how we can further utilize these bladder biomarkers in developing ideal and smart medical devices that would be applied in the clinic.
1. Coppens A, Speeckaert M, Delanghe J. The pre-analytical challenges of routine urinalysis. Acta Clin Belg. 2010;65(3):182-9. Epub 2010/07/31. doi: 10.1179/acb.2010.038. PubMed PMID: 20669786.
2. Howanitz PJ, Howanitz JH. Quality control for the clinical laboratory. Clin Lab Med. 1983;3(3):541-51. Epub 1983/09/01. PubMed PMID: 6357609.
3. Delanghe J, Speeckaert M. Preanalytical requirements of urinalysis. Biochem Med (Zagreb). 2014;24(1):89-104. Epub 2014/03/15. doi: 10.11613/BM.2014.011. PubMed PMID: 24627718; PubMed Central PMCID: PMCPMC3936984.
4. Fogazzi GB, Verdesca S, Garigali G. Urinalysis: core curriculum 2008. Am J Kidney Dis. 2008;51(6):1052-67. Epub 2008/05/27. doi: 10.1053/j.ajkd.2007.11.039. PubMed PMID: 18501787.
5. Bouatra S, Aziat F, Mandal R, Guo AC, Wilson MR, Knox C, et al. The human urine metabolome. PLoS One. 2013;8(9):e73076. Epub 2013/09/12. doi: 10.1371/journal.pone.0073076. PubMed PMID: 24023812; PubMed Central PMCID: PMCPMC3762851.
6. Dos Santos HG, Siltberg-Liberles J. Paralog-Specific Patterns of Structural Disorder and Phosphorylation in the Vertebrate SH3-SH2-Tyrosine Kinase Protein Family. Genome Biol Evol. 2016;8(9):2806-25. Epub 2016/08/16. doi: 10.1093/gbe/evw194. PubMed PMID: 27519537; PubMed Central PMCID: PMCPMC5630953.
7. Glorennec P, Serrano T, Fravallo M, Warembourg C, Monfort C, Cordier S, et al. Determinants of children's exposure to pyrethroid insecticides in western France. Environ Int. 2017;104:76-82. Epub 2017/04/30. doi: 10.1016/j.envint.2017.04.007. PubMed PMID: 28453973.
8. Filip S, Zoidakis J, Vlahou A, Mischak H. Advances in urinary proteome analysis and applications in systems biology. Bioanalysis. 2014;6(19):2549-69. Epub 2014/11/21. doi: 10.4155/bio.14.210. PubMed PMID: 25411698.
9. Apodaca G, Balestreire E, Birder LA. The uroepithelial-associated sensory web. Kidney Int. 2007;72(9):1057-64. Epub 2007/08/02. doi: 10.1038/sj.ki.5002439. PubMed PMID: 17667988.
10. Xing J, Reynolds JP. Diagnostic Advances in Urine Cytology. Surg Pathol Clin. 2018;11(3):601-10. Epub 2018/09/08. doi: 10.1016/j.path.2018.06.001. PubMed PMID: 30190143.
11. Nadkarni GN, Coca SG, Meisner A, Patel S, Kerr KF, Patel UD, et al. Urinalysis findings and urinary kidney injury biomarker concentrations. BMC Nephrol. 2017;18(1):218. Epub 2017/07/08. doi: 10.1186/s12882-017-0629-z. PubMed PMID: 28683730; PubMed Central PMCID: PMCPMC5499057.
12. Rhee EP. How Omics Data Can Be Used in Nephrology. Am J Kidney Dis. 2018;72(1):129-35. Epub 2018/02/27. doi: 10.1053/j.ajkd.2017.12.008. PubMed PMID: 29478865; PubMed Central PMCID: PMCPMC6019111.
13. Miyake M, Owari T, Hori S, Fujimoto K. Significant lack of urine-based biomarkers to replace cystoscopy for the surveillance of non-muscle invasive bladder cancer. Transl Androl Urol. 2019;8(Suppl 3):S332-S4. Epub 2019/08/09. doi: 10.21037/tau.2019.05.07. PubMed PMID: 31392161; PubMed Central PMCID: PMCPMC6642949.
14. Zhao M, Li M, Yang Y, Guo Z, Sun Y, Shao C, et al. A comprehensive analysis and annotation of human normal urinary proteome. Sci Rep. 2017;7(1):3024. Epub 2017/06/10. doi: 10.1038/s41598-017-03226-6. PubMed PMID: 28596590; PubMed Central PMCID: PMCPMC5465101.
15. Salomonis N. Integrative Analysis of Proteomics Data to Obtain Clinically Relevant Markers. Methods Mol Biol. 2018;1788:89-111. Epub 2017/11/18. doi: 10.1007/7651_2017_94. PubMed PMID: 29147916.
16. Zhang H, Fan Y, Xia L, Gao C, Tong X, Wang H, et al. The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer. Tumour Biol. 2017;39(3):1010428317691183. Epub 2017/03/28. doi: 10.1177/1010428317691183. PubMed PMID: 28345451.
17. Onile OS, Calder B, Soares NC, Anumudu CI, Blackburn JM. Quantitative label-free proteomic analysis of human urine to identify novel candidate protein biomarkers for schistosomiasis. PLoS Negl Trop Dis. 2017;11(11):e0006045. Epub 2017/11/09. doi: 10.1371/journal.pntd.0006045. PubMed PMID: 29117212; PubMed Central PMCID: PMCPMC5695849.
18. Adebayo AS, Mundhe SD, Awobode HO, Onile OS, Agunloye AM, Isokpehi RD, et al. Metabolite profiling for biomarkers in Schistosoma haematobium infection and associated bladder pathologies. PLoS Negl Trop Dis. 2018;12(4):e0006452. Epub 2018/05/01. doi: 10.1371/journal.pntd.0006452. PubMed PMID: 29708967; PubMed Central PMCID: PMCPMC5945272.
19. Zhong X, Isharwal S, Naples JM, Shiff C, Veltri RW, Shao C, et al. Hypermethylation of genes detected in urine from Ghanaian adults with bladder pathology associated with Schistosoma haematobium infection. PLoS One. 2013;8(3):e59089. Epub 2013/03/26. doi: 10.1371/journal.pone.0059089. PubMed PMID: 23527093; PubMed Central PMCID: PMCPMC3601097.
20. Mitsui T, Kira S, Ihara T, Sawada N, Nakagomi H, Miyamoto T, et al. Metabolomics Approach to Male Lower Urinary Tract Symptoms: Identification of Possible Biomarkers and Potential Targets for New Treatments. J Urol. 2018;199(5):1312-8. Epub 2017/11/28. doi: 10.1016/j.juro.2017.11.070. PubMed PMID: 29175111.
21. De Palma G, Di Lorenzo VF, Krol S, Paradiso AV. Urinary exosomal shuttle RNA: Promising cancer diagnosis biomarkers of lower urinary tract. Int J Biol Markers. 2019;34(2):101-7. Epub 2019/03/14. doi: 10.1177/1724600819827023. PubMed PMID: 30862241.
22. Junker K, Heinzelmann J, Beckham C, Ochiya T, Jenster G. Extracellular Vesicles and Their Role in Urologic Malignancies. Eur Urol. 2016;70(2):323-31. Epub 2016/03/01. doi: 10.1016/j.eururo.2016.02.046. PubMed PMID: 26924769.
23. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer. 2013;13(11):800-12. Epub 2013/10/18. doi: 10.1038/nrc3610. PubMed PMID: 24132111; PubMed Central PMCID: PMCPMC3986062.
24. Xu W, Yang L, Lee P, Huang WC, Nossa C, Ma Y, et al. Mini-review: perspective of the microbiome in the pathogenesis of urothelial carcinoma. Am J Clin Exp Urol. 2014;2(1):57-61. Epub 2014/08/16. PubMed PMID: 25126590; PubMed Central PMCID: PMCPMC4219294.
25. Alfano M, Canducci F, Nebuloni M, Clementi M, Montorsi F, Salonia A. The interplay of extracellular matrix and microbiome in urothelial bladder cancer. Nat Rev Urol. 2016;13(2):77-90. Epub 2015/12/17. doi: 10.1038/nrurol.2015.292. PubMed PMID: 26666363.
26. Wu P, Zhang G, Zhao J, Chen J, Chen Y, Huang W, et al. Profiling the Urinary Microbiota in Male Patients With Bladder Cancer in China. Front Cell Infect Microbiol. 2018;8:167. Epub 2018/06/16. doi: 10.3389/fcimb.2018.00167. PubMed PMID: 29904624; PubMed Central PMCID: PMCPMC5990618.
27. Markowski MC, Boorjian SA, Burton JP, Hahn NM, Ingersoll MA, Maleki Vareki S, et al. The Microbiome and Genitourinary Cancer: A Collaborative Review. Eur Urol. 2019;75(4):637-46. Epub 2019/01/19. doi: 10.1016/j.eururo.2018.12.043. PubMed PMID: 30655087.
28. Wroblewski LE, Peek RM, Jr., Wilson KT. Helicobacter pylori and gastric cancer: factors that modulate disease risk. Clin Microbiol Rev. 2010;23(4):713-39. Epub 2010/10/12. doi: 10.1128/CMR.00011-10. PubMed PMID: 20930071; PubMed Central PMCID: PMCPMC2952980.
29. Dahmus JD, Kotler DL, Kastenberg DM, Kistler CA. The gut microbiome and colorectal cancer: a review of bacterial pathogenesis. J Gastrointest Oncol. 2018;9(4):769-77. Epub 2018/08/29. doi: 10.21037/jgo.2018.04.07. PubMed PMID: 30151274; PubMed Central PMCID: PMCPMC6087872.
30. Spanogiannopoulos P, Bess EN, Carmody RN, Turnbaugh PJ. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. Nat Rev Microbiol. 2016;14(5):273-87. Epub 2016/03/15. doi: 10.1038/nrmicro.2016.17. PubMed PMID: 26972811; PubMed Central PMCID: PMCPMC5243131.
31. Geller LT, Barzily-Rokni M, Danino T, Jonas OH, Shental N, Nejman D, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357(6356):1156-60. Epub 2017/09/16. doi: 10.1126/science.aah5043. PubMed PMID: 28912244; PubMed Central PMCID: PMCPMC5727343.
32. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. Science. 2010;330(6005):831-5. Epub 2010/11/06. doi: 10.1126/science.1191175. PubMed PMID: 21051639; PubMed Central PMCID: PMCPMC3110694.
33. Domenici L, Monti M, Bracchi C, Giorgini M, Colagiovanni V, Muzii L, et al. D-mannose: a promising support for acute urinary tract infections in women. A pilot study. Eur Rev Med Pharmacol Sci. 2016;20(13):2920-5. Epub 2016/07/19. PubMed PMID: 27424995.
34. Bucevic Popovic V, Situm M, Chow CT, Chan LS, Roje B, Terzic J. The urinary microbiome associated with bladder cancer. Sci Rep. 2018;8(1):12157. Epub 2018/08/16. doi: 10.1038/s41598-018-29054-w. PubMed PMID: 30108246; PubMed Central PMCID: PMCPMC6092344.
35. Nickel JC, Stephens-Shields AJ, Landis JR, Mullins C, van Bokhoven A, Lucia MS, et al. A Culture-Independent Analysis of the Microbiota of Female Interstitial Cystitis/Bladder Pain Syndrome Participants in the MAPP Research Network. J Clin Med. 2019;8(3). Epub 2019/03/29. doi: 10.3390/jcm8030415. PubMed PMID: 30917614; PubMed Central PMCID: PMCPMC6462969.
36. Govender Y, Gabriel I, Minassian V, Fichorova R. The Current Evidence on the Association Between the Urinary Microbiome and Urinary Incontinence in Women. Front Cell Infect Microbiol. 2019;9:133. Epub 2019/05/24. doi: 10.3389/fcimb.2019.00133. PubMed PMID: 31119104; PubMed Central PMCID: PMCPMC6504689.
37. Bresler L, Price TK, Hilt EE, Joyce C, Fitzgerald CM, Wolfe AJ. Female lower urinary tract microbiota do not associate with IC/PBS symptoms: a case-controlled study. Int Urogynecol J. 2019. Epub 2019/04/18. doi: 10.1007/s00192-019-03942-9. PubMed PMID: 30993388.
38. Greenberg JH, Parikh CR. Biomarkers for Diagnosis and Prognosis of AKI in Children: One Size Does Not Fit All. Clin J Am Soc Nephrol. 2017;12(9):1551-7. Epub 2017/07/02. doi: 10.2215/CJN.12851216. PubMed PMID: 28667085; PubMed Central PMCID: PMCPMC5586584.
39. Psihogios NG, Gazi IF, Elisaf MS, Seferiadis KI, Bairaktari ET. Gender-related and age-related urinalysis of healthy subjects by NMR-based metabonomics. NMR Biomed. 2008;21(3):195-207. Epub 2007/05/03. doi: 10.1002/nbm.1176. PubMed PMID: 17474139.
40. Guo Z, Zhang Y, Zou L, Wang D, Shao C, Wang Y, et al. A Proteomic Analysis of Individual and Gender Variations in Normal Human Urine and Cerebrospinal Fluid Using iTRAQ Quantification. PLoS One. 2015;10(7):e0133270. Epub 2015/07/30. doi: 10.1371/journal.pone.0133270. PubMed PMID: 26222143; PubMed Central PMCID: PMCPMC4519152.
41. Chen Z, Kim J. Urinary proteomics and metabolomics studies to monitor bladder health and urological diseases. BMC Urol. 2016;16:11. Epub 2016/03/24. doi: 10.1186/s12894-016-0129-7. PubMed PMID: 27000794; PubMed Central PMCID: PMCPMC4802825.
42. Antunes-Lopes T, Coelho A, Pinto R, Barros SC, Cruz CD, Cruz F, et al. Urinary Neurotrophin Levels Increase in Women With Stress Urinary Incontinence After a Midurethral Sling Procedure. Urology. 2017;99:49-56. Epub 2016/10/05. doi: 10.1016/j.urology.2016.08.048. PubMed PMID: 27697460.
43. Kim J, Campbell AS, de Avila BE, Wang J. Wearable biosensors for healthcare monitoring. Nat Biotechnol. 2019;37(4):389-406. Epub 2019/02/26. doi: 10.1038/s41587-019-0045-y. PubMed PMID: 30804534.
44. McKeating KS, Aube A, Masson JF. Biosensors and nanobiosensors for therapeutic drug and response monitoring. Analyst. 2016;141(2):429-49. Epub 2015/12/04. doi: 10.1039/c5an01861g. PubMed PMID: 26631282.
45. Liu X, Lillehoj PB. Embroidered electrochemical sensors on gauze for rapid quantification of wound biomarkers. Biosens Bioelectron. 2017;98:189-94. Epub 2017/07/05. doi: 10.1016/j.bios.2017.06.053. PubMed PMID: 28675839.
46. Cho S, Park TS, Nahapetian TG, Yoon JY. Smartphone-based, sensitive microPAD detection of urinary tract infection and gonorrhea. Biosens Bioelectron. 2015;74:601-11. Epub 2015/07/21. doi: 10.1016/j.bios.2015.07.014. PubMed PMID: 26190472.
47. Noiphung J, Laiwattanapaisal W. Multifunctional Paper-Based Analytical Device for In Situ Cultivation and Screening of Escherichia coli Infections. Sci Rep. 2019;9(1):1555. Epub 2019/02/09. doi: 10.1038/s41598-018-38159-1. PubMed PMID: 30733495; PubMed Central PMCID: PMCPMC6367442.
48. Chuang CH, Du YC, Wu TF, Chen CH, Lee DH, Chen SM, et al. Immunosensor for the ultrasensitive and quantitative detection of bladder cancer in point of care testing. Biosens Bioelectron. 2016;84:126-32. Epub 2016/01/19. doi: 10.1016/j.bios.2015.12.103. PubMed PMID: 26777732.
49. Smittenaar P, Walker AK, McGill S, Kartsonaki C, Robinson-Vyas RJ, McQuillan JP, et al. Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer. Br J Cancer. 2018;119(2):220-9. Epub 2018/07/12. doi: 10.1038/s41416-018-0156-0. PubMed PMID: 29991697; PubMed Central PMCID: PMCPMC6048059.
50. Shan R, Sarkar S, Martin SS. Digital health technology and mobile devices for the management of diabetes mellitus: state of the art. Diabetologia. 2019;62(6):877-87. Epub 2019/04/10. doi: 10.1007/s00125-019-4864-7. PubMed PMID: 30963188.
51. Charpentier G, Benhamou PY, Dardari D, Clergeot A, Franc S, Schaepelynck-Belicar P, et al. The Diabeo software enabling individualized insulin dose adjustments combined with telemedicine support improves HbA1c in poorly controlled type 1 diabetic patients: a 6-month, randomized, open-label, parallel-group, multicenter trial (TeleDiab 1 Study). Diabetes Care. 2011;34(3):533-9. Epub 2011/01/27. doi: 10.2337/dc10-1259. PubMed PMID: 21266648; PubMed Central PMCID: PMCPMC3041176.
52. Rossi MC, Nicolucci A, Lucisano G, Pellegrini F, Di Bartolo P, Miselli V, et al. Impact of the "Diabetes Interactive Diary" telemedicine system on metabolic control, risk of hypoglycemia, and quality of life: a randomized clinical trial in type 1 diabetes. Diabetes Technol Ther. 2013;15(8):670-9. Epub 2013/07/13. doi: 10.1089/dia.2013.0021. PubMed PMID: 23844569.
53. Fernandez-Carames TM, Froiz-Miguez I, Blanco-Novoa O, Fraga-Lamas P. Enabling the Internet of Mobile Crowdsourcing Health Things: A Mobile Fog Computing, Blockchain and IoT Based Continuous Glucose Monitoring System for Diabetes Mellitus Research and Care. Sensors (Basel). 2019;19(15). Epub 2019/07/31. doi: 10.3390/s19153319. PubMed PMID: 31357725.
54. Jain SH, Powers BW, Hawkins JB, Brownstein JS. The digital phenotype. Nat Biotechnol. 2015;33(5):462-3. Epub 2015/05/13. doi: 10.1038/nbt.3223. PubMed PMID: 25965751.